Acute Intermittent Porphyria Market Research Report- Global Forecast till 2027

Acute Intermittent Porphyria Market Information: By Diagnosis (Blood, Urine, DNA, Serum), Treatment (Gonadotropin-Releasing Hormone Analogues, Prophylactic Hematin Infusions), End User (Hospitals & Clinics, Research Centers) - Global Forecast till 2027

ID: MRFR/Pharma/3291-HCR | February 2021 | Region: Global | 125 pages

Please note that the assessment period of report has been updated from 2017-2023 to 2020-2027. Cordially fill the sample form for updated data.

Market Scenario


Acute intermittent porphyria (AIP) is a genetic metabolic disorder. It affects the production of heme, the oxygen-binding prosthetic group of hemoglobin. Generally, it is characterized by a deficiency of the enzyme porphobilinogen deaminase.


The major causes of acute intermittent porphyria are abnormal urinary color, anorexia, insomnia, myalgia, and urinary retention. In some cases, AIP develops liver cancer (hepatocellular carcinoma), and some develop kidney failure. Other symptoms include gastrointestinal issues, urinary tract issues, neurological issues, psychiatric issues.


The acute intermittent porphyria market growth is majorly attributed to the increasing prevalence of the metabolic disorders, gastrointestinal issues, urinary tract issues, and healthcare insurance coverage. Moreover, increasing geriatric population will drive the market growth.


According to the Economic and Social Commission for Asia and the Pacific (ESCAP), in 2016, approximately 12.4% of the population in the region was over 60 years. According to Asian Development Bank, it was estimated that by 2050, 15% of total Malaysian population will be over 65 year old and in China, the elderly population will reach over 300 million by 2050. Thus, the increasing geriatric population in Asia is likely to help the growth of the market over the forecast period.


According to the WHO estimates, neurological disorders are responsible for 4.5%-11% of all illnesses including low or high income economies. This is far higher as compared to the number of respiratory ailments, gastrointestinal disorders, or cancers, and the burden is expected to increase further over the coming years.


According to the American Liver Foundation, there is an increasing the prevalence of liver disease in the U.S. from then last few years. It further stated that at least 30 million people have some form of liver disease.


However, availability of expensive treatment and poor reimbursement policies in the developing regions of the world are some of the factors, which may hamper the market growth during the forecast period.


The global acute intermittent porphyria market is expected to grow at a CAGR of 5.6 % during the forecast period 2017-2023. 


Intended Audience



  • Pharmaceutical Companies

  • Research and Development (R&D) Companies

  • Government Research Institute

  • Academic Institutes and Universities

  • Medical Research Laboratories

  • Market Research and Consulting Service Providers

  • Potential Investors

Figure: Global Acute Intermittent Porphyria Market, By Region Market Share, 2016 (%)
Acute Intermittent Porphyria Market

               Sources: Annual reports, Press release, White paper, Company presentation


 


Segmentations


The global acute intermittent porphyria market is segmented on the basis by diagnosis, by treatment, and by end user.


On the basis of diagnosis, it is segmented into blood test, urine test, serum test, DNA test, and others.  


On the basis of treatment, it is segmented into gonadotropin-releasing hormone analogues, prophylactic hematin infusions, and others.


On the basis of end user, it is segmented into hospitals & clinics, research centers, and others.


Regional Analysis


The Americas dominate the global acute intermittent porphyria market owing to well-developed technology, increasing patient with genetic metabolic disorders, high healthcare spending, and increasing government support for research & development. Furthermore, increased R&D activities and the concentration of major companies have fuelled the growth of the market in this region.


Europe holds the second position in the global acute intermittent porphyria market owing to the government support for research & development and availability of funds for research. This is expected to continue to drive the European market over the forecasted period. For instance, countries like Germany and France are increasing investment in the healthcare domain.  


Asia Pacific is the fastest growing acute intermittent porphyria market owing to the presence of rapidly developing healthcare technology, huge patient population, and high healthcare expenditure. Moreover, increasing demand for new treatment methods in countries like India and South Korea is likely to emerge as the fastest growing market across the globe. Furthermore, increasing demand for quality devices in the healthcare projected to lead to the use of advanced equipment, which, in turn, will increase the market growth of the acute intermittent porphyria in the region.


On the other hand, in the Middle East and Africa, blood disorders have become a huge problem due to limited screening, ignorance of diseases, and poor access to treatment.


 


Key Players


Some of key the players in the market are Dahaner (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Bio-Rad Laboratories, Inc.  (U.S.), Siemens AG (U.S.),  ARKRAY, Inc. (Japan), Sysmex Corporation (Japan), ACON Laboratories, Inc. (U.S.).


Research Methodology
Acute Intermittent Porphyria Market-


Sources: Annual reports, Press release, White paper, and Company presentation


 





Frequently Asked Questions (FAQ) :


Acute intermittent porphyria (AIP) is a genetic metabolic disorder. It affects the production of heme, the oxygen-binding prosthetic group of hemoglobin. Generally, it is characterized by a deficiency of the enzyme porphobilinogen deaminase.

The market is expected to exhibit a strong 5.6% CAGR over the forecast period from 2017 to 2023.

The growing awareness about porphyria and growth of the healthcare sector in emerging countries are the major drivers for the acute intermittent porphyria market.

The Americas hold a dominant 44% share in the global market.

Leading players in the acute intermittent porphyria market include Danaher, Bio-Rad Laboratories, and ARKRAY, among others.

Table of Content

1. Report Prologue

2. Market Introduction

2.1 Definition

2.2 Scope of the Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

3. Research Methodology

3.1 Introduction

3.2 Primary Research

3.3 Secondary research

3.4 Market Size Estimation

4. Market Dynamics

4.1 Drivers

4.2 Restrains

4.3 Opportunities

4.4 Challenges

4.5 Macroeconomic Indicators

4.6 Technology Trends & Assessment

5. Market Factor Analysis

5.1 Porters Five Forces Analysis

5.1.1 Bargaining Power of Suppliers

5.1.2 Bargaining Power of Buyers

5.1.3 Threat of New Entrants

5.1.4 Threat of Substitutes

5.1.5 Intensity of Rivalry

5.2 Value Chain Analysis

5.3 Investment Feasibility Analysis

5.4 Pricing Analysis

6. Global Acute Intermittent Porphyria Market, by Diagnosis

6.1 Introduction

6.2 Blood Test

6.2.1 Market Estimates & Forecast, 2020-2027

6.3 Urine Test

6.3.1 Market Estimates & Forecast, 2020-2027

6.4 Serum Test

6.4.1 Market Estimates & Forecast, 2020-2027

6.5 DNA test

6.4.1 Market Estimates & Forecast, 2020-2027

7. Global Acute Intermittent Porphyria Market, by Treatment

7.1 Introduction

7.2 Gonadotropin-Releasing Hormone Analogues

7.2.1 Market Estimates & Forecast, 2020-2027

7.3 Prophylactic Hematin Infusions

7.3.1 Market Estimates & Forecast, 2020-2027

8. Global Acute Intermittent Porphyria Market, by End User

8.1 Introduction

8.2 Hospitals & Clinics

8.2.1 Market Estimates & Forecast, 2020-2027

8.3 Research centers

8.3.1 Market Estimates & Forecast, 2020-2027

9. Global Acute Intermittent Porphyria Market, by Region

9.1 Introduction

9.2 Americas

9.2.1 North America

9.2.1.1 U.S.

9.2.1.1 Canada

9.2.2 South America

9.3 Europe

9.3.1 Western Europe

9.3.1.1 Germany

9.3.1.2 France

9.3.1.3 U.K.

9.3.1.4 Italy

9.3.1.5 Spain

9.3.1.6 Rest of Western Europe

9.3.2 Eastern Europe

9.4 Asia Pacific

9.4.1 Japan

9.4.2 China

9.4.3 India

9.4.4 Australia

9.4.5 Republic of Korea

9.4.6 Rest of Asia Pacific

9.5 The Middle East & Africa

9.5.1 United Arab Emirates

9.5.2 Saudi Arabia

9.5.3 Oman

9.5.4 Kuwait

9.5.5 Qatar

9.5.6 Rest of the Middle East & Africa

10 Company Landscape

10.1 Introduction

10.2 Market Share Analysis

10.3 Key Development & Strategies

10.3.1 Key Developments

11 Company Profiles

11.1 Dahaner Corporation

11.1.1 Company Overview

11.1.2 Product Overview

11.1.3 Financials

11.1.4 SWOT Analysis

11.2 F. Hoffmann-La Roche Ltd

11.2.1 Company Overview

11.2.2 Product Overview

11.2.3 Financial Overview

11.2.4 Key Developments

11.2.5 SWOT Analysis

11.3 Bio-Rad Laboratories, Inc

11.3.1 Company Overview

11.3.2 Product Overview

11.3.3 Financial Overview

11.3.4 Key Development

11.3.5 SWOT Analysis

11.4 Siemens AG

11.4.1 Company Overview

11.4.2 Product/Business Segment Overview

11.4.3 Financial Overview

11.4.4 Key Development

11.4.5 SWOT Analysis

11.5 ARKRAY, Inc.

11.5.1 Company Overview

11.5.2 Product Overview

11.5.3 Financial overview

11.5.4 Key Developments

11.6 Sysmex Corporation

11.6.1 Company Overview

11.6.2 Product Overview

11.6.3 Financial Overview

11.6.4 Key Developments

11.7 ACON Laboratories, Inc

11.7.1 Overview

11.7.2 Product Overview

11.7.3 Financials

11.7.4 Key Developments

11.7.5 SWOT Analysis

11.8 Others

12 MRFR Conclusion

12.1 Key Findings

12.1.1 From CEO’s View Point

12.1.2 Unmet Needs of the Market

12.2 Key Companies to Watch

12.3 Prediction of Pharmaceutical Industry

13 Appendix

LIST OF TABLES

Table 1 Acute Intermittent Porphyria Industry Synopsis, 2020-2027

Table 2 Global Acute Intermittent Porphyria Market Estimates and Forecast, 2020-2027, (USD Million)

Table 3 Global Acute Intermittent Porphyria Market by Region, 2020-2027, (USD Million)

Table 4 Global Acute Intermittent Porphyria Market by Diagnosis, 2020-2027, (USD Million)

Table 5 Global Acute Intermittent Porphyria Market by Treatment, 2020-2027, (USD Million)

Table 6 Global Acute Intermittent Porphyria Market by End Users, 2020-2027, (USD Million)

Table 7 North America Acute Intermittent Porphyria Market by Diagnosis, 2020-2027, (USD Million)

Table 8 North America Acute Intermittent Porphyria Market by Treatment, 2020-2027, (USD Million)

Table 9 North America Acute Intermittent Porphyria Market by End Users, 2020-2027, (USD Million)

Table 10 U.S. Acute Intermittent Porphyria Market by Diagnosis, 2020-2027, (USD Million)

Table 11 US Acute Intermittent Porphyria Market by Treatment, 2020-2027, (USD Million)

Table 12 US Acute Intermittent Porphyria Market by End Users, 2020-2027, (USD Million)

Table 13 Canada Acute Intermittent Porphyria Market by Diagnosis, 2020-2027, (USD Million)

Table 14 Canada Acute Intermittent Porphyria Market by Treatment, 2020-2027, (USD Million)

Table 15 Canada Acute Intermittent Porphyria Market by End Users, 2020-2027, (USD Million)

Table 16 South America Acute Intermittent Porphyria Market by Diagnosis, 2020-2027, (USD Million)

Table 17 South America Acute Intermittent Porphyria Market by Treatment, 2020-2027, (USD Million)

Table 18 South America Acute Intermittent Porphyria Market by End Users, 2020-2027, (USD Million)

Table 19 Europe Acute Intermittent Porphyria Market by Diagnosis, 2020-2027, (USD Million)

Table 20 Europe Acute Intermittent Porphyria Market by Treatment, 2020-2027, (USD Million)

Table 21 Europe Acute Intermittent Porphyria Market by End Users, 2020-2027, (USD Million)

Table 22 Western Europe Acute Intermittent Porphyria Market by Diagnosis, 2020-2027, (USD Million)

Table 23 Western Europe Acute Intermittent Porphyria Market by Treatment, 2020-2027, (USD Million)

Table 24 Western Europe Acute Intermittent Porphyria Market by End Users, 2020-2027, (USD Million)

Table 25 Eastern Europe Acute Intermittent Porphyria Market by Diagnosis, 2020-2027, (USD Million)

Table 26 Eastern Europe Acute Intermittent Porphyria Market by Treatment, 2020-2027, (USD Million)

Table 27 Eastern Europe Acute Intermittent Porphyria Market by End Users, 2020-2027, (USD Million)

Table 28 Asia Pacific Acute Intermittent Porphyria Market by Diagnosis, 2020-2027, (USD Million)

Table 29 Asia Pacific Acute Intermittent Porphyria Market by Treatment, 2020-2027, (USD Million)

Table 30 Asia Pacific Acute Intermittent Porphyria Market by End Users, 2020-2027, (USD Million)

Table 31 Middle East & Africa Acute Intermittent Porphyria Market by Diagnosis, 2020-2027, (USD Million)

Table 32 Middle East & Africa Acute Intermittent Porphyria Market by Treatment, 2020-2027, (USD Million)

Table 33 Middle East & Africa Acute Intermittent Porphyria Market by End Users, 2020-2027, (USD Million)

LIST OF FIGURES

Figure 1 Research Process

Figure 2 Segmentation for Global Acute Intermittent Porphyria Market

Figure 3 Segmentation Market Dynamics for Acute Intermittent Porphyria Market

Figure 4 Global Acute Intermittent Porphyria Market Share, by Diagnosis 2020

Figure 5 Global Acute Intermittent Porphyria Market Share, by Treatment 2020

Figure 6 Global Acute Intermittent Porphyria Market Share, by End Users, 2020

Figure 7 Global Acute Intermittent Porphyria Market Share, by Region, 2020

Figure 8 North America Acute Intermittent Porphyria Market Share, by Country, 2020

Figure 9 Europe Acute Intermittent Porphyria Market Share, by Country, 2020

Figure 10 Asia Pacific Acute Intermittent Porphyria Market Share, by Country, 2020

Figure 11 Middle East & Africa Acute Intermittent Porphyria Market Share, by Country, 2020

Figure 12 Global Acute Intermittent Porphyria Market: Company Share Analysis, 2020 (%)

Figure 13 Dahaner Corporation.: Key Financials

Figure 14 Dahaner Corporation.: Segmental Revenue

Figure 16 Dahaner Corporation.: Geographical Revenue

Figure 17 F. Hoffmann-La Roche Ltd: Key Financials

Figure 18 F. Hoffmann-La Roche Ltd: Segmental Revenue

Figure 19 F. Hoffmann-La Roche Ltd: Geographical Revenue

Figure 20 Bio-Rad Laboratories, Inc: Key Financials

Figure 21 Bio-Rad Laboratories, Inc: Segmental Revenue

Figure 22 Bio-Rad Laboratories, Inc: Geographical Revenue

Figure 23 Siemens AG: Key Financials

Figure 24 Siemens AG: Segmental Revenue

Figure 25 Siemens AG: Geographical Revenue

Figure 26 ARKRAY, Inc..: Key Financials

Figure 27 ARKRAY, Inc.: Segmental Revenue

Figure 28 ARKRAY, Inc.: Geographical Revenue

Figure 29 Sysmex Corporation: Key Financials

Figure 30 Sysmex Corporation: Segmental Revenue

Figure 31 Sysmex Corporation: Geographical Revenue

Figure 32 ACON Laboratories, Inc: Key Financials

Figure 33 ACON Laboratories, Inc: Segmental Revenue

Figure 34 ACON Laboratories, Inc: Geographical Revenue